Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - What's Next?

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $5.02, but opened at $4.65. Hypermarcas shares last traded at $4.65, with a volume of 185 shares trading hands.

Hypermarcas Trading Down 7.4%

The stock has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $3.73. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The firm has a market cap of $2.95 billion, a P/E ratio of 19.38 and a beta of 0.81.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $184.34 million during the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.

Hypermarcas Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, July 1st will be issued a $0.0345 dividend. This represents a dividend yield of 2.81%. The ex-dividend date is Monday, June 30th. Hypermarcas's payout ratio is 58.33%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.